R
Robert C. Flanigan
Researcher at Loyola University Medical Center
Publications - 209
Citations - 11667
Robert C. Flanigan is an academic researcher from Loyola University Medical Center. The author has contributed to research in topics: Renal cell carcinoma & Nephrectomy. The author has an hindex of 43, co-authored 201 publications receiving 11078 citations. Previous affiliations of Robert C. Flanigan include Loyola University Chicago & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Robert C. Flanigan,Sydney E. Salmon,Brent A. Blumenstein,Scott I. Bearman,Vivek Roy,Patrick C. McGrath,John R. Caton,Nikhil C. Munshi,E. David Crawford +8 more
TL;DR: Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferons therapy alone.
Journal ArticleDOI
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.
William J. Catalona,Jerome P. Richie,Frederick R. Ahmann,M'Liss A. Hudson,Peter T. Scardino,Robert C. Flanigan,Jean B. deKernion,Timothy L. Ratliff,Louis R. Kavoussi,Bruce L. Dalkin,W. Bedford Waters,Michael T. Macfarlane,Paula C. Southwick +12 more
TL;DR: In this paper, a prospective clinical trial at 6 university centers of 6,630 male volunteers 50 years old or older who underwent PSA determination (Hybritech Tandom-E or Tandem-R assays) and digital rectal examination was conducted.
Journal ArticleDOI
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial
William J. Catalona,Alan W. Partin,Kevin M. Slawin,Michael K. Brawer,Robert C. Flanigan,Anup Patel,Jerome P. Richie,Jean B. deKernion,Patrick C. Walsh,Peter T. Scardino,Paul H. Lange,Eric N.P. Subong,Robert E. Parson,Gail H. Gasior,Kathleen G. Loveland,Paula C. Southwick +15 more
TL;DR: Use of the percentage of free PSA can reduce unnecessary biopsies in patients undergoing evaluation for prostate cancer, with a minimal loss in sensitivity in detecting cancer.
Journal ArticleDOI
Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis
Robert C. Flanigan,G. Mickisch,Richard Sylvester,Cathy Tangen,H. Van Poppel,E. David Crawford +5 more
TL;DR: Cytoreductive nephrectomy appears to improve significantly overall survival in patients with metastatic renal cancer treated with interferon immunotherapy independent of patient performance status, the site of metastases and the presence of measurable disease.
Journal ArticleDOI
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial
William J. Catalona,Alan W. Partin,Kevin M. Slawin,Michael K. Brawer,Robert C. Flanigan,Anup Patel,Jerome P. Richie,Jean B. deKernion,Patrick C. Walsh,Peter T. Scardino,Paul H. Lange,Eric N.P. Subong,Robert E. Parson,Gail H. Gasior,Kathleen G. Loveland,Paula C. Southwick +15 more
TL;DR: Use of the percentage of free PSA can reduce unnecessary biopsies in patients undergoing evaluation for prostate cancer, with a minimal loss in sensitivity in detecting cancer.